SCHEMBL5560977

SCHEMBL5560977

O=C(O)C1CC1C(=O)c1csc(Cl)c1Cl

nearest known ligand 0.45

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.45
STING1 Q86WV6 8/20 0.35
LTC4S Q16873 4/20 0.34
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5560910 0.76 KMO (0.49) KMOSTING1LTC4SKMT2A
SCHEMBL5489140 0.73 DAO (0.45)
SCHEMBL5560640 0.72 KMO (0.57) KMOSTING1LTC4SKMT2AMAPT
SCHEMBL5561431 0.71 KMO (0.47) KMOSTING1LTC4SKMT2A
SCHEMBL5556099 0.70 NPC1 (0.30)
SCHEMBL5562600 0.68 DAO (0.55) KMOSTING1LTC4SKMT2A
SCHEMBL5560911 0.68 KMO (0.51) KMOLTC4SKMT2ATDP1MAPT
SCHEMBL5560715 0.67
SCHEMBL5091162 0.66 KMO (0.67) KMOLTC4SKMT2AMAPT
SCHEMBL16506371 0.66 KMO (0.62) KMOSTING1LTC4S

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1565451-B1 HALOTHIENOYL-CYCLOPROPANE-1-CARBOXYLIC ACID DERIVATIVES NEWRON PHARM SPA (IT) 2007-05-09 EP claimed
US-20060116329-A1 Halothenoyl-cyclopropane-1-carboxylic acid derivatives NEWRON PHARMACEUTICALS, S.P.A. (IT) 2006-06-01 US claimed
EP-1565451-A1 HALOTHENOYL-CYCLOPROPANE-1-CARBOXYLIC ACID DERIVATIVES Newron Pharmaceuticals S.p.A. (IT) 2005-08-24 EP claimed
WO-2004048361-A1 HALOTHENOYL-CYCLOPROPANE-1-CARBOXYLIC ACID DERIVATIVES NEWRON PHARMACEUTICALS S.P.A. (IT) 2004-06-10 WO claimed
EP-1424333-A1 Halothenoyl-cyclopropane-1-carboxylic acid derivatives Newron Pharmaceuticals S.p.A. (IT) 2004-06-02 EP claimed
EP-1565451-B1 HALOTHIENOYL-CYCLOPROPANE-1-CARBOXYLIC ACID DERIVATIVES NEWRON PHARM SPA (IT) 2007-05-09 EP disclosed
US-20060116329-A1 Halothenoyl-cyclopropane-1-carboxylic acid derivatives NEWRON PHARMACEUTICALS, S.P.A. (IT) 2006-06-01 US disclosed
EP-1565451-A1 HALOTHENOYL-CYCLOPROPANE-1-CARBOXYLIC ACID DERIVATIVES Newron Pharmaceuticals S.p.A. (IT) 2005-08-24 EP disclosed
WO-2004048361-A1 HALOTHENOYL-CYCLOPROPANE-1-CARBOXYLIC ACID DERIVATIVES NEWRON PHARMACEUTICALS S.P.A. (IT) 2004-06-10 WO disclosed
EP-1424333-A1 Halothenoyl-cyclopropane-1-carboxylic acid derivatives Newron Pharmaceuticals S.p.A. (IT) 2004-06-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116329-A1 Halothenoyl-cyclopropane-1-carboxylic acid derivatives KMO, HAO1, DAO KMO 1/4885STING1 3794/4885LTC4S 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.